RECRUITING

Phase 1/2 Study of VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease (VIVID)

Talk to us

Conditions

Von Willebrand DiseasesVon Willebrand Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Official Title

A Multi-Modular Trial to Evaluate VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease and Other Bleeding Disorders (VIVID)

Quick Facts

Study Start:2023-03-16
Study Completion:2029-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05776069

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Clinical Trials
CONTACT
650-466-8041
medinfo@star-therapeutics.com

Study Locations (Sites)

Orthopedic Institute for Children (UCLA)
Los Angeles, California, 90007
United States
UC Davis Medical Center
Sacramento, California, 95817
United States
University of Colorado School of Medicine
Aurora, Colorado, 80045
United States
Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory
Atlanta, Georgia, 30308
United States
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, 15213
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
University of Texas Southwestern
Dallas, Texas, 75235
United States
Washington Center for Bleeding Disorders
Seattle, Washington, 98101
United States
Versiti Comprehensive Center for Bleeding Disorders
Milwaukee, Wisconsin, 53233
United States

Collaborators and Investigators

Sponsor: Vega Therapeutics, Inc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-16
Study Completion Date2029-12

Study Record Updates

Study Start Date2023-03-16
Study Completion Date2029-12

Terms related to this study

Keywords Provided by Researchers

  • Von Willebrand Disorder

Additional Relevant MeSH Terms

  • Von Willebrand Diseases